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N-phthaloylamino acid hydroxamates of general formula C6H4(CO)2N-X-CONHOH
(X = amino acid residue) contain two biologically active groups in their structures, phthal-
imido and N-hydroxyamido.
Phthalimides have been known for a long time as plant growth regulators (1–3), bac-
teriostatics (4, 5) and fungicides (6). Thalidomide is the best-known phtalimide, a hyp-
notic/sedative drug with teratogenic effect. Nevertheless, thalidomide has never comp-
letely vanished as a therapeutic substance. The drug was found to have a powerful anti-
-inflammatory effect owing to its ability to inhibit the production of the cytokine tumour
necrosis factor alpha (TNF-), a potent stimulator of inflammation, cellular necrosis and
tissue damage in general (7). A recently discovered anticancer activity of thalidomide is
based on inhibition of the growth of new vessels, the process of angiogenesis (8). Thali-
domide is being increasingly used in the clinical management of a wide spectrum of im-
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Antibacterial and antifungal activity of N-phthaloylami-
no acid hydroxamates 1–3 C6H4(CO)2N-X-CONHOH,
X = amino acid residues of glycine, -alanine or D-phenyl-
glycine, was examined against 44 strains of Gram-posi-
tive and Gram-negative bacteria, and 10 species of yeasts.
The level of antimicrobial activity was established using
the in vitro agar assay and the standard broth dilution
susceptibility test. N-phthaloyl-D-phenylglycine-hydroxa-
mic acid (3), the substance with the highest lipophilicity
(log P), showed the best antibacterial activity, especially
against Gram-negative bacteria. Minimum inhibitory con-
centration of 3 was 0.008 mg mL–1 in the activity against
Yersinia enterocolitica O3, confirmed by a large inhibition
zone (30 mm) by the diffusion test. Hydroxamates inhi-
bit growth by chelation of the PDF enzyme metal in both
Gram-positive and Gram-negative bacteria, and LpxC en-
zyme in Gram-negative enzyme. Phthalimides appear to
contribute to inhibition by destabilizing m-RNA. Anti-
fungal activity of substances 1–3 is not very expressed.
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munologically-mediated and infectious diseases and cancers such as erythema nodosum
leprosum, multiple myeloma, renal and intestinal carcinoma, Behçet's, Crohn's and a
number of dermatologic diseases, rheumatoid arthritis and wasting syndrome in AIDS
(9–15). It is also effective for mycobacterial infection in the central nervous system such
as tuberculous meningitis caused by Mycobacterium bovis or Mycobacterium bacillus (16).
The way phthalimide reduces TNF- production is associated with induction of the de-
gradation process of TNF-alpha m-RNA (17–20).
The other active part in phthalimidohydroxamate structures is the N-hydroxyamido
group (hydroxamic acid). Some natural hydroxamic acids, products of various microor-
ganisms and fungi, act as growth factors or possess antitumour and antibacterial activity
(21). In biomedical sciences, hydroxamic acid moieties are used in the design of therape-
utics targeted at cancer, cardiovascular diseases, Alzheimer's disease, malaria, allergic and
infective diseases, metal poisoning and other metal overload diseases, e.g. after transfu-
sions in the genetic blood disease Cooley's anemia (22).
It seems that the powerful biological activity of structurally heterogeneous hydrox-
amic acids is related to their common ability to form very stable chelates with a variety
of metal ions. By blocking the metal ion in the active centre of enzyme, they can inhibit a
number of metalloenzymes. The process of enzymes inactivation, as supposed earlier,
involves redox reactions, e.g. inhibition of lipoxygenase is a result of the reduction of
Fe(III) to Fe(II) ions (23). Kinetic and EPR spectral evidence disputed such opinion (24).
Some important Zn(II) containing enzymes easily inhibited by hydroxamates are matrix
metalloproteinases (MMPs), angioconverting enzyme (ACE) and leukotriene A4 hydro-
lase (LTA4). Over-expression of MMPs has been implicated in a number of diseases, in-
cluding arthritis, multiple sclerosis and various human cancers. Dimartino and coautors
explained the anti-arthritic activity of hydroxamates by two parallel inhibitions, TNF-
and metalloproteinase (25). ACE enzyme plays a key role in the control of blood pressure
and the LTA4 enzyme is thought to be a pro-inflammatory mediator. Anti-inflammatory
activity of hydroxamates includes inhibitions of 5-lipoxygenase (5-LO) and cyclooxyge-
nase (COX), which are iron-containing metalloenzymes. The hydroxamate derivatives of
indometacin and ibuprofen appear to be dual inhibitors, of 5-LO and COX (23).
Antimicrobial activity of hydroxamates includes inhibition of enzymes necessary
for the growth of bacteria or yeasts as well as enzymes, the causes of pathogenicity. Ure-
ase, product of Helicobacter pylori (HP), is considered to be a major causative fact in pep-
tic ulcer diseases and it is also central to the virulence of Proteus mirabilis and Klebsiella
aerogenes. Ammonia produced by strong HP urease elevates the pH level in the stomach
and breaks gastric mucus, while the ammonia itself inhibits the consumption of oxygen
and reduces the production of ATP in gastric mucous cells or in the mitochondria. Ure-
ases are also implicated in the infection-induced urinary stones, pyelonephritis and he-
patic encephalopathy. Urease is a nickel-dependent metalloenzyme very effectively in-
hibited by hydroxamates (26–29).
Studies of hydroxamato dependent inhibition of Escherichia coli, as well as Pseudo-
monas aeruginosa and Aquifex aeolicus, have established that the main inhibitor-sensitive
enzyme in Gram-negative bacteria is LpxC UDP-3-(R-3-hydroxymyristoyl)-N-acetylglu-
cosamine-deacetylase. It is essential for the removal of acetyl group from 2-N position
of the lipid A precursor. Lipid A is part of lipopolysaccharide – a causative agent of pa-
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thogenicity in the outer membrane of Gram-negative bacteria. Enzyme LpxC is Zn(II)
amidase with zinc binding motifs not found in other zinc metalloenzymes (30–34).
Two enzymes are involved in the process of post-translational protein modificati-
ons. The first, peptide deformilase (PDF), is believed to be an essential enzyme in both
Gram-positive and Gram-negative bacteria and the second, methionine amino peptidase
(MAP), is not essential. PDF enzyme catalyzes the removal of the N-formyl group from
N-formyl-methionine. It is an iron(II)-containing metalloenzyme, not present in eukary-
otic protein synthesis (23). Although several different chelating groups for iron in the
PDF enzyme have been described, hydroxamate remains the preferred group (35–37).
EXPERIMENTAL
Chemistry
For antimicrobic examinations in this work, N-phthaloyl-amino acid hydroxamates
1–3 (Fig. 1) were synthesized from the amino acids glycine, -alanine and D-phenylglycine
in three steps. Amino acids were phthaloylated by phthalanhydride to N-phthaloylami-
no acids, which were converted by thionyl chloride to N-phthaloyl-aminoacylchlorides
and then translated into hydroxamic acids by hydroxylamine hydrochloride. Prepara-
tions were carried out according to our previously published method (38).
Solutions of samples for antimicrobial testing were made in water, in concentration
range 2–4 mg mL–1. In dissolution of compound 3, a small amount of dimethylsulfoxyde
was added (40 µL in 80 mL water). Glycine-hydroxamic acid used as standard was pur-
chased from the Sigma company (USA).
Microbiological tests
Antimicrobial activity testing was performed with 44 strains of Gram-positive and
Gram-negative bacteria and 10 species of yeasts from the collection of the Department of
Microbiology, Faculty of Pharmacy and Biochemistry, University of Zagreb. The bacterial
growth inhibition assays were carried out by the diffusion test and the dilution suscepti-
bility test. The agar diffusion method was applied according to the European Pharmaco-
poeia (39). Testing inocula 104–105 cells (0.5 mL portion) were swabbed onto solidified
Mueller-Hinton agar for bacteria and Sabouraud dextrose agar for yeasts. Steel cylinders
(8 x 10 mm) were placed on the agar and water solution of compound 1 or water solu-
tion with 0.05 % DMSO of compound 3 were applied in a volume of 0.25 mL. After 2 h
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Fig. 1. The structure of N-phthaloyl-glycine hydroxamic acid (1), N-phthaloyl--alanine
hydroxamic acid (2) and N-phthaloyl-D-phenylglycine hydroxamic acid (3).
of diffusion at 4 °C, the agar plates were incubated for 18–24 h at either 37 °C for bacteria,
or 48 h at 25 °C for yeasts. The diameters of clear inhibition zones around the cylinder
were measured after incubation if the tested substance inhibited bacterial or yeast growth.
Inhibitory concentrations (in mg mL–1) were determined by the broth dilution sus-
ceptibility test. Test strains were grown in a nutrition medium containing progressively
lower concentrations of the test substances. Dilutions of samples were made in the range
from 1 to 0.004 mg mL–1 for compounds 1 and 3 and starting from 2 to 0.004 mg mL–1
for compound 2. The prepared test dilutions were incubated at 37 °C for bacteria or 25
°C for yeasts. The last tube, as a positive growth control, was free of test compounds. In
the case of solution containing DMSO, two growth controls were made, with and without
DMSO. A sample was deemed free of viable germs if the nutritient solution appeared
clear after incubation. All samples showing no turbidity were subcultured into Mueller-
-Hinton or Sabouraud agar. Concentrations at which the microorganisms did not grow in
fresh medium were bactericidal (BC) or fungicidal (FC) concentrations, i.e., the concen-
trations that irreversibly kill microorganisms. The lowest concentration among BC is the
minimum bactericidal concentration (MBC) while the minimum fungicidal concentra-
tion (MFC) is the lowest among FC concentrations.
The subcultures from clear tubes that result in growth into fresh medium lacking
test substance show a bacteriostatic (BS) or fungistatic (FS) concentration, which rever-
sibly inhibit growth and do not kill the present microorganisms. The lowest sample con-
centration that prevents appearance of turbidity was established to be the minimum in-
hibitory concentration (MIC) and can be cidal or static (40).
RESULTS AND DISCUSSION
It has been established by the diffusion antibacterial test that N-phthaloyl-D-phenyl-
glycine hydroxamic acid (3) inhibits 27/30 strains of bacteria in contrast to N-phthaloyl-
-glycine hydroxamic acid (1) which inhibits 16/30 strains (Table I). The zones of inhibition
were also bigger in compound 3 (average 21.3 mm) compared to those of compound 1
(13.9 mm). The dilution test showed the best activity of compound 3 against Yersinia en-
terocolitica 03 BS (MIC) = 0.008 mg mL–1; BC (MBC) = 0.016 mg mL–1, some strains of
Enterococcus sp. (MIC = 0.008 mg mL–1; MBC = 0.016 mg mL–1) and Sarcina lutea (MIC =
0.016 mg mL–1; MBC = 0.031 mg mL–1) (Table II). Compound 1 showed the best activity
against Enterococcus sp. (for strains ER1 and ER4 MIC = 0.016 mg mL–1) and Sarcina lutea
(MIC = 0.063 mg mL–1) (Table III). Dilution test of N-phthaloyl--alanine hydroxamic acid
(2) showed moderate or low activity against 15/15 bacteria, the best of which were ag-
ainst Sarcina lutea (MIC = 0.063 mg mL–1; MBC = 0.125 mg mL–1) (Table IV). Enterococcus
faecalis showed with compound 2 the same MIC values, but the measured MBC concen-
tration was very high (2 mg mL–1).
The influence of compounds 1–3 on the growth of yeasts, especially Candida, is shown
in Table V. Growth inhibitions were not prominent. The lowest inhibitory concentration
was 0.063 mg mL–1 determined for compound 3 against Candida parapsilosis. The growth
control of the water solution with 0.05 vol. % DMSO (used for dissolution of compound
3) was positive for bacteria and yeasts.
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The differences in inhibition of investigated N-phthaloylamino acid hydroxamates
can be explained by the level of lipophilicity (log P, octanol/water partition coefficient)
of structures 1–3. In general, the most lipophilic compound, N-phthaloyl-D-phenylgly-
cine hydroxamic acid (3, log P = –6.776), showed the highest inhibition and the least li-
pophilic compound N-phthaloyl-glycine hydroxamic acid (1, log P = –8.367) the weakest
one. Compound 2 (N-phthaloyl--alanine hydroxamic acid, log P = –7.837) gave the ex-
pected values between compounds 3 and 1, closer to 1 (41). For example, BS (MIC) for
compound 3 was 0.008, for 2 it was 0.125 and for compound 1, 0.500 mg mL–1 for Yersi-
nia. The results for Pseudomonas aeruginosa were as follows: 0.250 for compound 3 and
0.500 mg mL–1 for compound 2, while hydroxamic acid 1 showed no inhibition. In some
cases compound 2 was more active than 1, but never compared to compound 3.
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Gram-positive Bacillus cereus ATCC 11778 – 21
Bacillus subtilis NCTC 8236 16 –
Sarcina flava R28 20 30
Sarcina lutea ATCC 9341 8 23
Staphylococcus aureus ATCC 6538P 13 20
Staphylococcus aureus SR2 12 19
Staphylococcus aureus SR5 15 21
Staphylococcus aureus SJ3 11 22
Staphylococcus aureus SJ4 13 18
Enterococcus sp. ER1 16 21
Enterococcus sp. ER2 15 20
Enterococcus sp. ER3 16 22
Enterococcus sp. ER4 17 19
Enterococcus sp. ER5 15 21
Listeria monocytogenes – –
Gram-negative Klebsiella oxytoca 1 12 32
Salmonella enteritidis 17 –
Proteus mirabilis 1 – 11
Proteus mirabilis 1A – 9
Proteus mirabilis 1B – 9
Proteus rettgeri – 10
Proteus vulgaris – 12
Proteus sp. – 13
Escherichia coli R 16 – 30
Escherichia coli R30 – 29
Escherichia coli R19 – 30
Escherichia coli 0157; A2 – 31
Escherichia coli 0128; B12 – 30
Pseudomonas aeruginosa – 21
Yersinia enterocolitica O3 7 30
The big difference between the behaviour of the most lipophilic structure 3 and the
least lipophilic 1 against Gram-negative bacteria is noteworthy. The fact that the more
lipophilic substance showed better inhibition can be explained by its easier passing through
the lipophilic membrane where it inhibits the LpxC enzyme. To be useful against the
LpxC enzyme, an inhibitor should recognize Zn coordination and the surfaces in the en-
zyme active site – a hydrophobic tunnel occupied by appropriately positioned fatty acid
substituents.
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1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004
Gram-positive bacteria
Bacillus cereus ATCC11778 BCa BSb + + + + + + +
Sarcina flava R28 BCa BCa BCa BCa BSb + + + +
Sarcina lutea ATCC 9341 BCa BCa BCa BCa BCa BC BSb + +
Staphylococcus aureus ATCC6538P BCa BCa BSb + + + + + +
Staphylococcus aureus SR2 BCa BCa BCa BSb + + + + +
Staphylococcus aureus SR5 BCa BCa BCa BSb + + + + +
Staphylococcus aureus SJ3 BCa BCa BSb + + + + + +
Staphylococcus aureus SJ4 BCa BCa BSb + + + + + +
Enterococcus sp. ER1 BCa BCa BCa BCa BCa BC BSb + +
Enterococcus sp. ER2 BCa BCa BCa BCa BCa BCa BCa BSb +
Enterococcus sp. ER3 BCa BCa BCa BCa BCa BC BSb + +
Enterococcus sp. ER4 BCa BCa BCa BCa BCa BC BSb + +
Enterococcus sp. ER5 BCa BCa BCa BCa BCa BCa BCa BSb +
Listeria monocytogenes BCa BSb + + + + + + +
Gram-negative bacteria
Klebsiella oxytoca BCa BSb + + + + + + +
Proteus mirabilis 1 BCa BSb + + + + + + +
Proteus mirabilis 1A BCa BSb + + + + + + +
Proteus rettgeri BCa BCa BSb + + + + + +
Proteus vulgaris BCa BCa BSb + + + + + +
Proteus sp. BCa BSb + + + + + + +
Esherichia coli R16 BCa BCa BSb + + + + + +
Esherichia coli R30 BCa BCa BCa BSb + + + + +
Esherichia coli R 19 BCa BCa BCa BSb + + + + +
Esherichia coli 0157; A2 BCa BCa BSb + + + + + +
Esherichia coli 0128; B12 BCa BCa BSb + + + + + +
Yersinia enterocolitica O3 BCa BCa BCa BCa BCa BCa BCa BSb +
+ Growth of bacteria.
a Total inhibition of growth.
b Partial inhibition of growth (here identical to MIC).
Structure-affinity relationships for aliphatic LpxC inhibitors with saturated C6–C12
chain revealed that the more lipophilic inhibitor, with longer chain lengths of C10, exhi-
bited significant binding affinity for Aquifex Aeolicus Lpxc to chain C6 (33). Stronger LpxC
inhibition does not automatically mean better antibacterial activity. Very hydrophobic
groups often exhibit excellent enzyme inhibitory activity while showing little to no anti-
bacterial activity. Such steric bulky groups may become trapped in the cell membrane,
where they can associate with bacterial lipid bilayers, bind to bacterial proteins, interact
with some enzymes or receptors, resulting in low inhibitor concentrations in the cyto-
plasm. Despite the fact that antibacterial and LpxC enzyme inhibitory properties are not
strictly correlated, it is most important that there are no compounds that exhibit signifi-
cant antibacterial activity but lack enzyme inhibitory activity (30).
Antibacterial activity of N-phthaloyl-amino acid hydroxamates 1–3 against both Gram-
-positive and Gram-negative bacteria can be explained by inhibition of the PDF enzyme.
Comparison of the results obtained from isolated PDF and the whole cell system showed
that inhibitions were similar. Thus, the whole cell antibacterial activity could be mainly
attributed to the inhibition of PDF enzyme as the most important enzyme in protein
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Table III. Bactericidal (BC) and bacteriostatic (BS) concentrations of
N-phthaloyl-glycine hydroxamic acid (1)
Bacteria
Concentration (mg mL–1)
1.000 0.500 0.250 0.125 0.063 0.031 0.016 0.008
Gram-positive bacteria
Bacillus subtilis NCTC8236 BC BS + + + + + +
Sarcina flava R28 BC BC BS + + + + +
Sarcina lutea ATCC 9341 BC BC BC BC BS + + +
Staphylococcus aureus ATCC 6538P BC BS BS + + + + +
Staphylococcus aureus SR2 BC BC BS + + + + +
Staphylococcus aureus SR5 BC BC BS + + + + +
Staphylococcus aureus SR3 BC BS + + + + + +
Staphylococcus aureus SR4 BC BS + + + + + +
Enterococcus sp. ER1 BC BC BC BC BC BS + +
Enterococcus sp. ER2 BC BC BC BC BC BC BS +
Enterococcus sp. ER3 BC BC BC BC BC BS + +
Enterococcus sp. ER4 BC BC BC BC BC BC BS +
Enterococcus sp. ER5 BC BC BC BC BC BS + +
Gram-negative bacteria
Klebsiella oxytoca BC BS + + + + + +
Salmonella enteritidis + + + + + + + +
Yersinia enterocolitica O3 BC BS + + + + + +
+ Growth of bacteria.
synthesis of bacteria. Quantitative structure relationship (QSAR) studies demonstrated
the importance of small lipophilic substituents for increasing inhibitory activity, but not
of bulky lipophilic ones (23, 37). The barriers determinated by the volume of -amino-
acyl hydroxamates were established also by studying HP urease inhibition (23, 36).
From the mentioned results on structure-inhibition relationships from the referen-
ces, it can be seen that inhibition, in general, increases with lipophilicity but is sterically
limited. With regard to the fact that antibacterial activity and inhibition of the PDF en-
zyme are almost identical and, what is more, this enzyme participates in all bacteria, it
can be concluded that the inhibitions of bacteria with N-phthaloyl-amino acid hydroxa-
mates 1–3, presented in this work, are caused first by inhibition of PDF enzyme. The
presented results further indicate participation of LpxC enzyme inhibition because of
the great difference in the behavior of Gram-negative bacteria. The process of inhibition
also includes other metalloenzymes, certainly some specific urease in some Gram-nega-
tive bacteria.
The presented results of inhibition dependence on the hydrophobicity of hydroxa-
mato structures 1–3 are in agreement with the published ones.
In general, hydroxamic acids are capable of inhibiting bacterial enzymes due to
their high chelating affinity towards metal ion in the active centre of the enzyme (28, 32,
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Table IV. Bactericidal (BC) and bacteriostatic (BS) concentrations of
N-phthaloyl--alanine hydroxamic acid (2)
Bacteria
Concentration (mg mL–1)
2.000 1.000 0.500 0.250 0.125 0.063 0.031
Gram-positive bacteria
Bacillus subtilis BS + + + + + +
Bacillus cereus BS BS + + + + +
Bacillus pumilus BS + + + + + +
Sarcina lutea BC BC BC BC BC BS +
Staphylococcus aureus BC BC BS + + + +
Enterococcus sp. BS BS BS BS + + +
Enterococcus faecalis BC BS BS BS BS BS +
Listeria monocytogenes BC BS BS + + + +
Gram-negative bacteria
Esherichia coli BC BS BS BS BS + +
Salmonella enteritidis BC BC BS + + + +
Klebsiella oxytoca BC BS BS BS + + +
Pseudomonas aeruginosa BC BS BS + + + +
Proteus mirabilis BC BS BS + + + +
Yersinia sp. BC BC BC BC BS + +
Serratia sp. BC BS BS BS + + +
+ Growth of bacteria.
37). Phthalimides contribute to bacterial growth inhibition by mechanisms that are not
quite clear, probably by destabilizing m-RNA of bacterial enzymes (10, 17, 18).
To find if phthalimido or hydroxamato groups contribute to better inhibition, the in-
fluence of N-phthaloyl-glycine and glycine hydroxamic acid on the growth of bacteria
was also examined. As expected, the inhibition of most bacteria was stronger with N-
phthaloyl-glycine hydroxamic acid (1) than with N-phthaloyl-glycine or with glycine
hydroxamic acid. A similar result was obtained for the growth inhibition of Lepidium sa-
tivum L. (38). According to the differences in activity between hydroxamato and phtha-
limido moieties, phthalimido structure was more effective against some bacteria, hyd-
roxamato structure against the other.
Further, no regularity among activities against yeasts was found for compounds 1–3.
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Table V. Fungicidal (FC) and fungistatic (FS)





1.000 0.500 0.250 0.125 0.063 0.031
Candida tropicalis 1 FCa FCa FSb + + +
2 FCa FCa FCa FSb + +
3 FCa FSb FSb + + +
Candida albicans 1 FSb + + + + +
2 FCa FCa FSb FSb + +
3 FCa FSb FSb + + +
Candida glabrata 1 FCa FSb + + + +
2 FCa FSb + + + +
3 FCa FSb + + + +
Candida kefyr 1 FCa FCa FCa FCa + +
2 FSb FSb + + + +
3 FCa FCa FCa FCa + +
Candida parapsilosis 1 FSb FSb + + + +
2 FCa FSb + + + +
3 FCa FCa FCa FCa FSb +
Criptococus neoformans 1 FCa + + + + +
2 FCa FSb + + + +
3 FCa FCa FCa FCa + +
Candida krusei 2 FCa FSb + + + +
Geotrichum sp. 2 FSb FSb + + + +
Saccharomyces cerevisiae 2 FSb + + + + +
Hansenula anomala 2 FSb + + + + +
+ Growth of yeasts.
a Total inhibition of growth.
b Partial inhibition of growth (identical to MIC).
CONCLUSIONS
The examined N-phthaloylamino acid hydroxamates 1–3 showed a broad antibacte-
rial activity, especially the activity of the most lipophilic compound, N-phthaloyl-D-phe-
nylglycine hydroxamic acid (3).MIC was 0.008 mg mL–1 for compound 3 against Yersinia
enterocolitica O3, confirmed by a large inhibition zone (30 mm) in the diffusion test.
The inhibition of both Gram-positive and Gram-negative bacteria by the examined
phthalimido-hydroxamates can be contributed to inhibition of probably the most impor-
tant enzyme for the growth of bacteria, the PDF enzyme. Owing to the fact that this en-
zyme is not involved in the eukariotic cytoplasmatic protein synthesis and therefore
PDF inhibited bacteria can not develop resistance against antimicrobial agents, PDF is a
potentially attractive target for antibacterial drug design.
The inhibition of Gram-negative bacteria by the examined substances includes also
inactivation of the LpxC enzyme, the key of endotoxin, as well as some specific enzymes
e.g. urease, one of exotoxins. Owing to its inhibitory activity depending on lipophilicity,
N-phthaloyl-D-phenylglycine hydroxamic acid (3) was established to possess the best
antimicrobial activity against Gram-negative bacteria.
The results of the antibacterial investigations described in this work are in agree-
ment with some earlier published data and provide another contribution to the struc-
ture-antibacterial activity relationship.
The inhibitory activity of tested substances against yeasts was rather weak. The best
MIC value (0.063 mg mL–1) was obtained in the determination of compound 3 activity
against Candida parapsilosis.
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S A @ E T A K
Antimikrobna aktivnost N-ftaloil-aminokiselinskih hidroksamata
JULIJA MATIJEVI]-SOSA i ZDENKA CVETNI]
Ispitano je djelovanje N-ftaloil-aminokiselinskih hidroksamata 1–3 op}e formule
C6H4(CO)2N-X-CONHOH (X = aminokiselinski ostatak glicina, -alanina ili D-fenilglici-
na) na 44 soja Gram-pozitivnih i Gram-negativnih bakterija i 10 vrsta kvasaca. Antibak-
terijski i antifungalni u~inak testiran je postupkom difuzije na hranjivom agaru i standard-
nom metodom dilucije. Najbolja inhibicija rasta, osobito izra`ena prema Gram-negativnim
bakterijama, utvr|ena je za N-ftaloil-D-fenilglicin hidroksamsku kiselinu (3) s najve}om
lipofilno{}u. Za soj Yersinia enterocolitica O3 minimalna inhibitorna koncentracija (0,008
mg mL–1) potvr|ena je inhibicijskom zonom od 30 mm pomo}u difuzijskog testa. Hidro-
ksamati inhibiraju rast keliranjem metala PDF enzima kod Gram-pozitivnih i Gram-ne-
gativnih bakterija, te LpxC enzima kod Gram-negativnih bakterija. Ftalimido struktura
pridonosi inhibiciji, pretpostavlja se, destabilizacijom m-RNA. Antifungalna aktivnost
spojeva 1–3 nije osobito izra`ena.
Klju~ne rije~i: hidroksamska kiselina, ftalimid, antibakterijsko djelovanje, lipofilnost
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